125 results about "Invasion and migration" patented technology

The invention discloses an siRNA of a targeted long-chain noncoding RNA DDX11-AS1 and applications thereof in liver cancer treatment. Through designing and synthesizing the siRNA of the DDX11-AS1 andtransfecting a liver cancer cell line with the siRNA, it is proved that the siRNA can targetedly inhibit expression of the DDX11-AS1, can significantly suppress liver cancer cell proliferation, invasion and migration and can induce liver cancer cell apoptosis. A novel target point for research and development of a liver cancer treatment medicine is provided.

The invention discloses 1-(4-hydroxyl-3-methoxycarbonylphenyl)-[beta]-carboline-3-formyl-Leu-Asp-Val represented as the following formula, wherein a standard abbreviation of the Leu-Asp-Val is LDV. The invention also discloses a preparation method, a nano structure and an anti-tumor effect of the compound, discloses the effect of the compound of inhibiting adhesion, invasion and migration of tumor cells and further discloses anti-inflammation and anti-thrombus effects of the compound and discloses the applications of the compound in medicine.

The invention discloses (6S)-3-acetyl-4-oxo-4,6,7,12-tetrahydroindole [2,3-a] quinolizine-6-formyl-Arg-Gly-Asp-Ser structured as follows, wherein the standard abbreviation of Arg-Gly-Asp-Ser is RGDS. The invention discloses a preparation method therefor, a nanostructure thereof, antitumor action thereof and action thereof in resisting adhesion, invasion and migration of tumor cells, and illustrates application thereof in medical science. The formula is shown in t he description.

The invention belongs to the field of genetic engineering, and in particular relates to application of PVT1 in preparation and diagnosis of preeclampsia and target drug therapy. The down-regulation of PVT1 in a placenta tissue of a preeclampsia pregnant woman is related to the generation and development of preeclampsia, and the low-expression-level PVT1 is closely related to the pathogenesis of preeclampsia. The proliferation, apoptosis, invasion, migration and the like of trophoblast cells of the preeclampsia pregnant woman are affected by changing the expression of PVT1, and the proliferation, invasion and migration of trophoblast cells can be promoted by enhancing the expression of PVT1.

The invention belongs to the field of gene engineering, and particularly relates to application of LINC00961 to prediction of non-small-cell lung cancer (NSCLC) prognosis and treatment of target spot medicine. In the NSCLC, down-regulation of the LINC00961 is closely related to clinical stages and tumor sizes, and is closely related to patient prognosis at the same time. The invasion, migration and the like of NSCLC cells are influenced by changing expression of the LINC00961, so that the LINC00961 expression is enhanced, and the invasion and migration of the NSCLC cells can be restrained.

The invention discloses 1-(4-isopropyl propyl)-beta-carboline-3-formyl-Trp-Trp-Trp-Lys-Glu structured as follows, a preparation method therefor, a nanostructure thereof, antitumor action thereof, action thereof in resisting adhesion and invasion and migration of tumor cells, and illustrates application thereof in medical science. The formula is shown in the description.

The invention belongs to the field of biological medicines, and particularly relates to an application of CDCA8 in the preparation of a drug for treating ovarian cancer. The invention provides an application of a reagent for inhibiting CDCA8 gene expression or inhibiting a CDCA8 gene expression product in the preparation of a drug for treating ovarian cancer and/or inhibiting proliferation, invasion and migration of ovarian cancer cells and at the same time promoting ovarian cancer cell cycle arrest and apoptosis. In addition, the inhibition of the expression of CDCA8 or the inhibition of theCDCA8 gene expression product can enhance the sensitivity of ovarian cancer cells to chemotherapeutic drugs cisplatin and olaparib by adjusting the cell cycle and inhibiting DNA damage repair. A new thought is provided for screening drugs for treating ovarian cancer, especially serous ovarian cancer, and a new method is provided for enhancing the sensitivity to traditional ovarian cancer chemotherapeutic drugs.

The invention discloses an application of FGF21 in preparation of a medicine for treating colorectal cancer, and belongs to the technical field of medicines. The FGF21 protein provided by the invention is a secretory protein composed of about 210 amino acids. The invention finds for the first time that the FGF21 has the effect of treating colorectal tumor, and cytological experiments and animal experiments prove that the FGF21 can inhibit proliferation, invasion and migration of a colorectal tumor cell line, and can obviously reduce the size of a tumor focus in a mouse model. The medicine which is used for treating colorectal cancer and is prepared by taking the FGF21 as an active substance has the effects of being good in safety, long in medicine effect lasting time, capable of protectingorgans from being damaged and capable of improving lipid metabolism disorder.

The invention relates to an application of aryl naphthalene type lignan in preparing a medicine for resisting the prostate cancer. The aryl naphthalene type lignan is a compound as follows: 6-hydroxyl-4beta-(4-hydroxyl-3-methoxyphenyl)-3alpha-hydroxymethyl-7-methoxyl-3, 4-dihydro-2-naphthaldehyde. The invention also provides an extraction method of aryl naphthalene type lignan compounds. The application has the advantages that by in-vitro test of prostate cancer cells of a human on the compound, the aryl naphthalene type lignan can inhibit proliferation, invasion and migration of prostate cancer cells with different types, and has good activity for resisting the prostate cancer, so that the aryl naphthalene type lignan can be used for preparing the medicine for resisting the prostate cancer.

The invention relates to Trp-Trp-Trp decapeptide modified beta-carboline, discloses a preparation method and the nanometer structure of beta-carboline, relates to the in-vivo and in-vitro antitumor effects of beta-carboline, and relates to effects of beta-carboline to resist tumor cell adhesion invasion and migration. Therefore, the invention discloses application of Trp-Trp-Trp decapeptide modified beta-carboline to prepare antitumor medicines and prepare medicines resisting tumor cell adhesion invasion and migration. The invention belongs to the field of biological medicine.

The invention relates to the field of biological medicines and especially relates to a chiral nanometer fiber and its preparation method and use. The chiral nanometer fiber raw material mainly comprises zinc ions and chiral amino acid. The diameter of the chiral nanometer fiber is in a range of 120-160nm. The chiral nanometer fiber can be used for preparation of drugs for treating and preventing tumor cells. The chiral nanometer fiber can influence extracellular HSP90 functions thereby influencing an extracellular HSP90 related signal path, can well inhibit tumor invasion and migration activity, does not enter into cells, and does not influence cell normal physiological functions. When the chiral nanometer fiber is degraded in vivo, the degraded ingredient zinc ions and aspartic acid have very good biocompatibility and does not damage the body at an appropriate treatment concentration.

The invention provides an evodiamine derivative. The evodiamine derivative is prepared by taking an anthranilic acid compound and tryptamine as initial raw materials through a condensation reaction and a one-step ring closing reaction catalyzed by lewis acid. The evodiamine derivative prepared by the preparation method disclosed by the invention has dual inhibition effects on topoisomerase I/II, so a broad-spectrum anti-tumor effect is achieved. The derivative can induce apoptosis of cancer cells and retard proceeding to a G2/M period in a concentration-dependent manner, and has an effect of inhibiting invasion and migration of cancer cells in vitro. The derivative has a good tumor growth inhibition effect in a nude mouse transplantation tumor model, has no obvious toxicity at a cell level and an animal level, has good safety and can be applied to preparation of anti-tumor drugs.

The invention discloses an siRNA, an siRNA plasmid and a lentivirus for targeted inhibition of EGFL9 gene expression, as well as a construction method of the lentivirus, and application of the SiRNA,the siRNA plasmid and the lentivirus in preparation of liver cancer treatment drugs, and provides an action target of the EGFL9 gene for liver cancer treatment by researching the expression level of the EGFL9 in liver cancer tissues. An siRNA sequence for targeted inhibition of expression of the EGFL9 gene, and corresponding siRNA expression plasmids and siRNA lentiviruses are designed; therefore,the expression of the EGFL9 gene in liver cancer cells can be efficiently inhibited, the invasion and migration capability of the liver cancer cells can be effectively inhibited, and the EGFL9 gene targeted therapeutic drug is of great significance to the preparation of the EGFL9 gene targeted therapeutic drug for liver cancer; meanwhile, the method can be used for developing corresponding targeted therapeutic drugs such as RNAi, monoclonal antibodies and small molecule antagonists, so that an effective method is provided for developing targeted therapeutic drugs for treating liver cancer byaiming at the EGFL9.

The invention relates to a long non-coding RNA and application of the long non-coding RNA in diagnosis of preeclampsia and preparation of a target drug for curing the preeclampsia, belongs to the field of genetic engineering, and particularly relates to application of Linc00284 in diagnosis of preeclampsia and preparation of a target drug for curing the preeclampsia. The up-regulation of the Linc00284 in the placenta of a pregnant woman with the preeclampsia is related to the occurrence and development of the preeclampsia, the Linc00284 with the high expression level is closely related to thepathogenesis of the preeclampsia, the proliferation, apoptosis, invasion, migration and the like of trophoblast cells of the pregnant women with the preeclampsia are affected by changing the expression of the Linc00284, and knock-down of the Linc00284 can promote the invasion and migration abilities of the trophoblast cells.

The invention discloses application of hsa_circ_0007444 in preparation of a medicine for treating ovarian cancer. According to the research, a hsa_circ_0007444 overexpression plasmid vector is prepared, and the function of the hsa_circ_0007444 overexpression plasmid vector in ovarian cancer cells is verified by overexpression lentivirus and specific siRNA. The overexpression hsa_circ_0007444 can obviously inhibit proliferation, invasion and migration of ovarian cancer and promote apoptosis of ovarian cancer, and knockdown of hsa_circ_0007444 can obviously promote proliferation, invasion and migration of ovarian cancer and inhibit apoptosis of ovarian cancer. Meanwhile, hsa_circ_0007444 overexpression can inhibit growth and lung metastasis of ovarian cancer in vivo and is an important target for treating ovarian cancer.

The invention belongs to the technical field of medical biology, and particularly relates to an ovarian cancer marker and application thereof. The invention proposes that the expression level of PRPF6 in ovarian cancer is closely related to FIGO staging and is irrelevant to age, differentiation degree and lymph node metastasis for the first time. The expression levels of the PRPF6 gene and the encoded protein thereof in the ovarian cancer drug-resistant cells/tissues are detected through PCR, immunohistochemistry and other methods, high expression of the PRPF6 in the drug-resistant cells/tissues is found, and it is clear that the PRPF6 can be used as the ovarian cancer paclitaxel drug-resistant marker. By inhibiting the expression level of the PRPF6, the drug resistance of paclitaxel can be inhibited, the invasion and migration of ovarian cancer cells can be reduced, cell apoptosis can be induced, and tumor growth can be inhibited, so that the PRPF6 inhibitor can be used as a potential target spot for the paclitaxel chemotherapy drug resistance treatment of the ovarian cancer, and a reference basis is provided for clinical diagnosis and treatment of the chemotherapy drug resistance type ovarian cancer. The method has wide application prospects and huge potential social benefits.